Fasoracetam: The Racetam Built for ADHD and Anxiety the FDA Forgot About

Fasoracetam is the racetam most biohackers have never heard of, and it’s the one with the most interesting clinical pedigree of any compound in the family. It made it through phase 2 trials for adolescent ADHD with metabotropic glutamate receptor mutations. Then the program quietly stalled, and the molecule landed on the gray market.

For the enhanced man interested in cognitive enhancement that goes beyond stimulant-and-coffee, fasoracetam is one of the more interesting tools in the kit. We’re going to break down the mechanism, what the trials actually showed, and the realistic dosing.

What Fasoracetam Is

Fasoracetam (NS-105, MGS0028) is a racetam-class nootropic developed by Nippon Shinyaku in the 1990s. It’s structurally related to piracetam and aniracetam but acts on a fundamentally different set of receptors. Where the older racetams primarily modulate the cholinergic system, fasoracetam primarily targets the metabotropic glutamate receptors — specifically mGluR1, mGluR2, and mGluR3 — and the GABA-B system.

That receptor profile is unusual and explains why fasoracetam has a different subjective effect than other racetams. Users report less of the “sharp focus” associated with piracetam and more of an anxiolytic, dampening effect on intrusive thinking. Hence the ADHD and anxiety angle in clinical development.

The Adolescent ADHD Trials

The most rigorous fasoracetam research was done by Hakon Hakonarson’s group at Children’s Hospital of Philadelphia. They identified a genetic subgroup of ADHD patients with mutations in the GRM7 and other metabotropic glutamate receptor genes. They hypothesized that fasoracetam, with its mGluR-modulating profile, would specifically help this subgroup.

The 2017 phase 2 trial enrolled 30 adolescents with ADHD and confirmed mGluR mutations. After 5 days of fasoracetam, ADHD-RS-IV scores dropped significantly. The drug was well tolerated. The trial was small, but the effect size was meaningful — the kind of result that should have driven a phase 3 program.

Then the corporate restructuring happened. The molecule never made it to a definitive trial. It’s the textbook example of a promising compound stranded by funding mechanics rather than scientific failure. the enhanced man does not pretend that pharmaceutical development is purely meritocratic. It’s not.

Tony huge law of Biochemistry Physics #8: Promising Compounds Get Orphaned All the Time

If a molecule has phase 2 efficacy data and a clean safety profile and then disappears from the development pipeline, the most likely explanation is patent economics, not failure. Fasoracetam is in that category. So is a long list of off-patent compounds the Enhanced Man learns to evaluate on their own merits — see our take on peptide safety hypocrisy for the philosophical foundation.

What Fasoracetam Actually Does

1. Glutamate System Rebalancing

The metabotropic glutamate receptors regulate the tonic level of glutamate signaling — not the rapid action-potential firing, but the background tone. When this tone is off, you get either anxiety and racing thoughts or attentional drift. Fasoracetam upregulates these receptors over chronic dosing, with the result of normalizing the tone.

2. GABA-B Modulation

Fasoracetam is also a GABA-B agonist at higher doses. This is the same receptor that baclofen hits and that GHB hits. The fasoracetam effect is much milder — you don’t get the sedation or the dependence pattern. But the GABA-B component contributes to the anxiolytic feel.

3. Cholinergic Component

Fasoracetam mildly upregulates acetylcholine release. Less than aniracetam or pramiracetam, but enough that adding a choline source (alpha-GPC or CDP-choline at 250-500 mg) is worth doing during a fasoracetam cycle.

4. Subjective Effect Profile

Reports converge on:

• Reduced intrusive worry and rumination.
• Easier task initiation in ADHD-pattern individuals.
• Slightly enhanced verbal fluency.
• Better sleep onset (mild GABA-B effect).
• Effects often build over 5-10 days, unlike piracetam where it’s more immediate.

The Real Protocol

Dosing

• Starting dose: 10-20 mg orally, twice daily. Most people land in this range.
• Trial range: up to 30 mg three times daily — but most users don’t need this much.
• Cycle: 4-8 weeks ON, then 2-4 weeks OFF. Receptor adaptation is real with chronic mGluR modulators.

Stacking

• Choline source: Alpha-GPC 300-600 mg daily. Prevents the headache that some users report when running racetams without enough acetylcholine substrate.
• L-Theanine: 100-200 mg. Synergistic anxiolytic effect without sedation.
• Magnesium glycinate: 400-600 mg before bed. NMDA modulation complements fasoracetam’s mGluR work.
• Don’t stack with phenibut. GABA-B doubling is a bad idea. Ditto with kava or baclofen.

How It Compares to Other Cognitive Tools

Fasoracetam has the cleanest profile if you specifically want non-stimulant anxiety reduction with ADHD-pattern attention support. It will not give you a stimulant kick. If you want a stimulant kick, that’s a different conversation.

Side Effects

• Headache if cholinergic substrate is low — fix with alpha-GPC.
• Mild fatigue at higher doses — drop the dose.
• GI upset — take with food.
• Tolerance over weeks — cycle off.
• No sexual side effects, no addiction profile, no withdrawal pattern at the doses described.

The Hypocrisy Angle

Doctors will hand a 12-year-old with ADHD a prescription for amphetamine — Schedule II, with a documented profile of growth suppression, cardiovascular effects, and rebound issues — without a second thought. The same medical system calls fasoracetam “experimental” even though the phase 2 ADHD trial in adolescents was clean and the safety profile is benign by every parameter we have. The patent expired before the indication could be locked in. That’s the only difference. The Enhanced Man does the analysis himself and stops outsourcing his cognitive optimization to a system that gates the safer molecules.

Sourcing and Quality

Fasoracetam is sold by research chemical vendors. Two important rules: third-party COA (certificate of analysis) is non-negotiable, and the molecule should be the monohydrate form for stability. Anything else is sketchy. Cost should run roughly $30-60 for a 90-day supply at the doses described.

The ForeverMan Take

Fasoracetam is a niche tool. It’s not for everyone. If you have an ADHD-pattern attention profile combined with anxiety and you’ve been forced into the stimulant/SSRI gauntlet by conventional medicine, fasoracetam is one of the most interesting non-stimulant alternatives with actual phase 2 data behind it.

Run a controlled trial of yourself: 4 weeks on, with structured tracking of focus, anxiety, and sleep. If the numbers move, keep it in rotation as a 6-8 week cycle quarterly. If they don’t, drop it. The Enhanced Man does not stay on a compound that’s not earning its place.

Pair with the rest of the cognitive supplement stack, lock in bloodwork, and watch the protocol on Tony huge enhanced.